Search:

Postcode lottery fears over new cancer drug

A new ‘wonder drug’ for breast cancer could save the lives of 1,000 women a year, stunning trial results have shown. Aromasin has been hailed as ‘excellent news for women’ but there are fears that a combination of cost and red tape may mean many are denied the drug

More: continued here

Leave a Reply

Powered by Article Dashboard

Related News


  • Children in poorer areas ‘missing life-saving vaccinations’
    Millions of children are not getting life-saving innoculations because of a postcode lottery of care caused by the way Labour pays doctors. Children in poorer parts of the country are up to 60 times more likely to miss out on vital vaccinations


  • Herceptin approved for NHS use
    Herceptin, the breast cancer 'wonder drug', should be made available to early-stage sufferers on the NHS, the Government's health watchdog has announced. The move - which will come into effect next month - follows the granting of a UK licence for the drug by European authorities


  • Heart drug cuts cancer risk
    A common blood pressure drug taken by millions of Britons could cut the risk of cancer, say scientists. A major study found that taking ACE inhibitors halves the risk of developing throat, pancreatic and colon cancer. Find out everything you need to know about these amazing drugs here


  • Leukaemia drug ‘major discovery in cancer fight’
    A leukaemia drug that a government watchdog wanted to deny to NHS patients is being hailed as the biggest breakthrough in cancer therapy for a generation


  • Obesity In Prostate Cancer Patients Predicts Cancer Recurrence And Progression
    Obesity in a patient is an independent predictor of whether localized prostate cancer will progress following radiotherapy treatment, say researchers at M. D. Anderson Cancer Center.In a study reported in the Aug. 1 issue of the journal Cancer, researchers found that moderately and severely obese patients had a 99 percent greater risk of developing biochemical failure (an early marker of cancer progression) than other patients. [click link for full article]